低分子量肝素改善小鼠皮肤微循环及光损伤修复的研究

doi:10.3969/j.issn.2097-2806.2026.09.009

摘要/Abstract

摘要：

低分子量肝素（LMWH）的非抗凝活性逐渐成为研究的热点，但其在皮肤保护中的作用尚未充分研究。本研究通过细胞和动物模型，研究了LMWH的改善微循环作用和光损伤修复功能，并初步研究了其作用机制。在微循环调控方面，LMWH通过上调一氧化氮（NO）含量促进皮肤微循环，加速水肿消退。在细胞层面，LMWH对胶原合成具有双向调控作用：显著上调胶原IV和胶原XVII的表达，同时抑制UVB诱导的基质金属蛋白酶-9 （MMP-9）表达，阻断胶原降解通路。动物模型进一步证实，LMWH可有效减轻UVB诱导的皮肤皲裂、干燥、皮层增厚及胶原破坏。综上，LMWH具有改善微循环、维持胶原蛋白稳态以及抵抗光损伤的作用，具备作为护肤品添加成分的开发潜力。

关键词: 低分子量肝素, 微循环, 光损伤, 基质金属蛋白酶-9, 胶原蛋白

Abstract:

The non-anticoagulant activities of low molecular weight heparin （LMWH） have attracted increasing attention; however, its role in cutaneous protection remains insufficiently investigated. This study explored the effects of LMWH on improving microcirculation and repairing photodamage using cellular and animal models, while preliminarily elucidating its underlying mechanisms of action. In terms of microcirculation regulation, LMWH promotes cutaneous microcirculation by upregulating nitric oxide （NO） levels and accelerating the resolution of edema, thereby providing foundational support for tissue repair. At the cellular level, LMWH exerts a bidirectional regulatory effect on collagen synthesis: it significantly upregulates the expression of collagen IV and collagen XVII to strengthen basement membrane integrity, while simultaneously inhibiting UVB-induced expression of matrix metalloproteinase-9 （MMP-9） to suppress collagen degradation pathways. Animal models further confirm that LMWH effectively alleviates UVB-induced skin chapping, dryness, epidermal thickening, and collagen disruption. Collectively, LMWH improves cutaneous microcirculation, maintains collagen homeostasis, and protects against photodamage, highlighting its potential as an active ingredient in functional skincare formulations.

Key words: low molecular weight heparin, microcirculation, photodamage, MMP-9, collagen

中图分类号:

TQ658

许忠良, 任晓婷, 刘金龙, 孙旭. 低分子量肝素改善小鼠皮肤微循环及光损伤修复的研究[J]. 日用化学工业（中英文）, 2026, 56(9): 1207-1213.

Zhongliang Xu, Xiaoting Ren, Jinlong Liu, Xu Sun. Study on the improvement of cutaneous microcirculation and photodamage repair by low-molecular-weight heparin in mice[J]. China Surfactant Detergent & Cosmetics, 2026, 56(9): 1207-1213.

图/表 8

图1

图2

图3

表1

图4

图5

图6

图7

参考文献 18

[1]	Wang P, Chi L, Zhang Z, et al. Heparin: An old drug for new clinical applications[J]. Carbohydr. Polym., 2022, 295: 119818. doi: 10.1016/j.carbpol.2022.119818
[2]	Liu J, Xie Y, Shu X, et al. Value function assessment to different RL algorithms for heparin treatment policy of patients with sepsis in ICU[J]. Artif. Intell. Med., 2024, 147: 102726. doi: 10.1016/j.artmed.2023.102726
[3]	Gockel L M, Heyes M, Li H, et al. Inhibition of tumor-host cell interactions using synthetic heparin mimetics[J]. ACS Appl. Mater. Interfaces, 2021, 13 (6) : 7080-7093. doi: 10.1021/acsami.0c20744
[4]	Huang X, Qin D, Morais S, et al. Photoacoustic-Strain (PAS) imaging for tissue microcirculation assessment[J]. IEEE Trans. Med. Imaging, 2025, 44 (8) : 3299-3310. doi: 10.1109/TMI.2025.3562141
[5]	Ko J, Lee M J, Jeong W, et al. Single-walled carbon nanotube-guided topical skin delivery of tyrosinase to prevent photoinduced damage[J]. ACS Nano., 2023, 17 (20) : 20473-20491. doi: 10.1021/acsnano.3c06846 pmid: 37793020
[6]	Li F, Zhi J, Zhao R, et al. Discovery of matrix metalloproteinase inhibitors as anti-skin photoaging agents[J]. Eur. J. Med. Chem., 2024, 267: 116152. doi: 10.1016/j.ejmech.2024.116152
[7]	Cao M, Qiao M, Sohail M, et al. Non-anticoagulant heparin derivatives for COVID-19 treatment[J]. Int. J. Biol. Macromol., 2023, 226: 974-981. doi: 10.1016/j.ijbiomac.2022.12.090
[8]	Zou Z Y, Huang J J, Luan Y Y, et al. Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: A retrospective analysis from the MIMIC-IV database[J]. Burns Trauma, 2022, 10. Doi:10.1093/burnst/tkac029.
[9]	Petrovic M T, Djordjevic-Dikic A, Giga V, et al. The Coronary ARteriogenesis with combined heparin and exercise therapy in chronic refractory angina (CARHEXA) trial: A double-blind, randomized, placebo-controlled stress echocardiographic study[J]. Eur. J. Prev.Cardiol., 2021, 28 (13) : 1452-1459.
[10]	Chen Q, Lin W, Tang Y, et al. Curcumin targets YAP1 to enhance mitochondrial function and autophagy, protecting against UVB-induced photodamage[J]. Front. Immunol., 2025, 16: 1566287. doi: 10.3389/fimmu.2025.1566287
[11]	Lutze S, Westphal T, Jünger M, et al. Microcirculation disorders of the skin[J]. J. Dtsch. Dermatol. Ges., 2024, 22 (2) : 236-264. doi: 10.1111/ddg.15242 pmid: 38229208
[12]	Breslin J W. Edema and lymphatic clearance: molecular mechanisms and ongoing challenges[J]. Clin. Sci. (Lond.), 2023, 137 (18) : 1451-1476. doi: 10.1042/CS20220314
[13]	Li X, Yuan D, Zhang P, et al. A neuron-mast cell axis regulates skin microcirculation in diabetes[J]. Diabetes, 2024, 73 (10) : 1728-1741. doi: 10.2337/db23-0862
[14]	Wei K, He L, Li X, et al. The β-glucan from lentinus alleviates UVB-induced dermal fibroblasts senescence and skin photoaging[J]. Int. J. Biol. Macromol., 2025, 329: 147834. doi: 10.1016/j.ijbiomac.2025.147834
[15]	Yao W, Chen X, Li X, et al. Current trends in the anti-photoaging activities and mechanisms of dietary non-starch polysaccharides from natural resources[J]. Crit. Rev. Food. Sci. Nutr., 2022, 62 (32) : 9021-9035. doi: 10.1080/10408398.2021.1939263
[16]	Kandan P V, Balupillai A, Kanimozhi G, et al. Opuntiol prevents photoaging of mouse skin via blocking inflammatory responses and collagen degradation[J]. Oxid. Med. Cell. Longev., 2020.Doi:10.1155/2020/5275178.
[17]	Yu C, Yang H, Wang L, et al. Surface modification of polytetrafluoroethylene (PTFE) with a heparin-immobilized extracellular matrix (ECM) coating for small-diameter vascular grafts applications[J]. Mater. Sci. Eng. C Mater. Biol. Appl., 2021, 128: 112301. doi: 10.1016/j.msec.2021.112301
[18]	Luo J, Wang Z, Fan B, et al. A comparative study of the effects of different fucoidans on cefoperazone-induced gut microbiota disturbance and intestinal inflammation[J]. Food Funct., 2021, 12(19) : 9087-9097. doi: 10.1039/d1fo00782c pmid: 34388231

组别	剂量/（mg/g）	n	左耳耳重/mg	右耳耳重/mg	耳肿胀值/mg
NC	0	10	25.71±2.25	35.58±3.64	9.87±1.32
PC	5	8	25.32±2.16	29.94±1.89	4.62±0.83^a
LMWH （低）	0.1	8	25.39±1.90	35.07±2.63	9.68±1.26^b
LMWH（中）	0.5	7	26.14±2.38	32.94±1.51	6.80±0.59^a
LMWH（高）	1	8	25.68±1.87	30.76±1.76	5.08±0.75^a